Plaeger S, Bass H Z, Nishanian P, Thomas J, Aziz N, Detels R, King J, Cumberland W, Kemeny M, Fahey J L
Center for Interdisciplinary Research in Immunology and Disease (CIRID) and the Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California, 90095, USA.
Clin Immunol. 1999 Feb;90(2):238-46. doi: 10.1006/clim.1998.4646.
One hundred and eighteen HIV-infected homosexual men without AIDS and 40 control seronegative homosexual men were assessed for 23 parameters reflecting immune activation to determine prognostic significance for occurrence of AIDS. Samples cryopreserved in 1987-1989 were analyzed, with AIDS occurrence determined by mid-1992. Cell surface antigens assessed on the major lymphocyte subsets were HLA-DR, CD38, CD71, and CD25. Soluble serum molecules assessed were tumor necrosis factor alpha, soluble TNFalpha receptor II, soluble IL-2 receptor alpha, neopterin, and beta2-microglobulin. Using a proportional hazards model, prognostic markers included decreased CD4 number and percentage; increased sIL-2R, neopterin, and beta2M; increased percentage HLA-DR+ total lymphocytes and CD4+ cells; increased CD38+ total lymphocytes and CD8+ cells; increased CD71+ total lymphocytes and CD4+ cells; and decreased CD25+ total lymphocytes and CD19+ cells. After adjustment for CD4 cell levels, sIL-2R, neopterin, beta2M, and CD25+ CD19 cells remained significant, indicating that additional information about AIDS risk was provided by these markers.
对118名未患艾滋病的HIV感染同性恋男性和40名血清反应阴性的对照同性恋男性进行了评估,检测了反映免疫激活的23项参数,以确定其对艾滋病发生的预后意义。分析了1987 - 1989年冷冻保存的样本,艾滋病的发生情况截至1992年年中确定。在主要淋巴细胞亚群上评估的细胞表面抗原为HLA - DR、CD38、CD71和CD25。评估的可溶性血清分子为肿瘤坏死因子α、可溶性TNFα受体II、可溶性IL - 2受体α、新蝶呤和β2 - 微球蛋白。使用比例风险模型,预后标志物包括CD4数量和百分比降低;可溶性IL - 2受体、新蝶呤和β2M升高;HLA - DR + 总淋巴细胞和CD4 + 细胞百分比升高;CD38 + 总淋巴细胞和CD8 + 细胞升高;CD71 + 总淋巴细胞和CD4 + 细胞升高;以及CD25 + 总淋巴细胞和CD19 + 细胞降低。在对CD4细胞水平进行调整后,可溶性IL - 2受体、新蝶呤、β2M和CD25 + CD19细胞仍然具有显著意义,表明这些标志物提供了有关艾滋病风险的额外信息。